Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan

Circ Heart Fail. 2020 Jun;13(6):e006946. doi: 10.1161/CIRCHEARTFAILURE.119.006946. Epub 2020 Jun 2.
No abstract available

Keywords: heart failure; hospitalization; prognosis; sacubitril-valsartan; systems biology.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminobutyrates / adverse effects
  • Aminobutyrates / therapeutic use*
  • Angiotensin II Type 1 Receptor Blockers / adverse effects
  • Angiotensin II Type 1 Receptor Blockers / therapeutic use*
  • Biphenyl Compounds
  • Disease Progression
  • Drug Combinations
  • Heart Failure / diagnostic imaging
  • Heart Failure / drug therapy*
  • Heart Failure / mortality
  • Heart Failure / physiopathology
  • Hospitalization
  • Humans
  • Neprilysin / antagonists & inhibitors
  • Protease Inhibitors / adverse effects
  • Protease Inhibitors / therapeutic use*
  • Recovery of Function
  • Tetrazoles / adverse effects
  • Tetrazoles / therapeutic use*
  • Time Factors
  • Treatment Outcome
  • Valsartan
  • Ventricular Function, Left / drug effects*
  • Ventricular Remodeling / drug effects*

Substances

  • Aminobutyrates
  • Angiotensin II Type 1 Receptor Blockers
  • Biphenyl Compounds
  • Drug Combinations
  • Protease Inhibitors
  • Tetrazoles
  • Valsartan
  • Neprilysin
  • sacubitril and valsartan sodium hydrate drug combination